

Use of an Aseptically Processed Dehydrated Human Amnion and Chorion Membrane Improves Likelihood and Rate of Healing in Chronic Diabetic Foot Ulcers: A Prospective, Randomised, Multi-Centre Clinical Trial in 80 Patients *International Wound Journal* - July, 2018

Lawrence A. DiDomenico, DPM FACFAS | Dennis P. Orgill, MD PhD | Robert D. Galiano, MD | Thomas E. Serena, MD FACS | Marissa J. Carter, PhD MA | Jarrod P. Kaufman, MD | Nathan J. Young | Allen M. Jacobs, DPM | Charles M. Zelen, DPM FACFAS

AmnioBand® Membrane: Diabetic Foot Ulcers

MTF Biologics recently completed a multi-center, prospective, randomized, 80 patient, controlled clinical trial evaluating the use of AmnioBand Membrane in chronic diabetic foot ulcer (DFU) applications. As an advanced treatment option, AmnioBand Membrane significantly outperformed the use of standard of care (SOC) alone, with half the number of treatments needed. But, don't just take our word for it. Check out the stats to see why AmnioBand Membrane is receiving rave reviews from clinicians like you.


Expect more with less: Greater healing in less time

~3.5x
more patients healed
at 6 weeks


Greater than
2.5x
more patients healed
at 12 weeks

Complete closure in
~1/2
the time versus
SOC alone

Percentage of Wounds Healed at 6 weeks



Percentage of Wounds Healed at 12 weeks



*p-value at 6 weeks = 0.0000019 and p-value at 12 weeks = 0.000006. (p < 0.05 is considered statistically significant)

Average Time to Closure



*p = 0.000006

AmnioBand® Membrane CLINICAL HIGHLIGHTS

Significant wound area reduction with just a few treatments

Wound Area Reduction

At 4 weeks, AmnioBand Membrane plus SOC provided wound area reduction of greater than 85%.

Mean number of AmnioBand Applications per Healed Wound

At 6 weeks  3.7 treatments

At 12 weeks  4 treatments


Lowest cost to closure

85%
less than
Dermagraft®

80%
less than
Apligraf®

37%
less than EpiFix®

Mean Graft Cost to Closure at 12 Weeks (\$USD)



¹Paulos, M. & Papadopoulos, D. Poster presented at Diabetic Limb Salvage Conference, September 22-24, 2011, Washington, DC.

²Zelen CM, et al. *Int Wound J.* 2016 Apr;13(2):272-82.

³DiDomenico, Orgill, Galiano, Serena, et al. *Int Wound J.* 2018;1-9.

Heal wounds in a fraction of the time, at a fraction of the cost.

AmnioBand Membrane is the most cost effective treatment option in the industry for **three** reasons:

Greater healing in less time | Fewer applications | Wide variety of sizes

125 May Street, Edison, NJ, USA 08837 • 800-433-6567 • +1 (732) 661-0202 • mtfbiologics.org

Dermagraft® is a registered trademark of Organogenesis, Inc.

Apligraf® is a registered trademark of Novartis.

EpiFix® is a registered trademark of MiMedx Group, Inc.

MTF Biologics is a trademark and AmnioBand is a registered trademark of the Musculoskeletal Transplant Foundation.

©2018 Musculoskeletal Transplant Foundation. All rights reserved. MKTG -1217 Rev. 0


Wound Care